Vaccines, reverse vaccinology, and bacterial pathogenesis

Cold Spring Harbor Perspectives in Medicine

Volumn 3, Issue 5, 2013, Pages

  Delany, Isabel ^a   Rappuoli, Rino ^a   Seib, Kate L ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIA (MICROORGANISMS); NEISSERIA MENINGITIDIS;

EID: 84877103716     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a012476     Document Type: Article

References (121)

1. Abbot E.L., Smith WD, Siou GP, Chiriboga C, Smith RJ, Wilson J.A., Hirst BH, Kehoe MA. 2007. Pili mediate specific adhesion of Streptococcus pyogenes to human tonsil and skin. Cell Microbiol 9: 1822-1833.
2. Acharya I.L., Lowe CU, Thapa R, Gurubacharya VL, Shrestha M.B., Cadoz M, Schulz D, Armand J, Bryla DA, Trollfors B., et al. 1987. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report. N Engl J Med 317: 1101-1104.
3. Bagnoli F., Moschioni M, Donati C, Dimitrovska V, Ferlenghi I, Facciotti C, Muzzi A, Giusti F, Emolo C, Sinisi A., et al. 2008. A second pilus type in Streptococcus pneumoniae is prevalent in emerging serotypes and mediates adhesion to host cells. J Bacteriol 190: 5480-5492.
4. Bambini S., Muzzi A, Olcen P, Rappuoli R, Pizza M, Comanducci M. 2009. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 27: 2794-2803.
5. Barocchi M.A., Ries J, Zogaj X, Hemsley C, Albiger B, Kanth A., Dahlberg S, Fernebro J, Moschioni M, Masignani V., et al. 2006. A pneumococcal pilus influences virulence and host inflammatory responses. Proc Natl Acad Sci 103: 2857-2862.
6. Bartolini E., Frigimelica E, Giovinazzi S, Galli G, Shaik Y, Genco C., Welsch JA, GranoffDM, Grandi G, Grifantini R. 2006. Role of FNR and FNR-regulated, sugar fermentation genes in Neisseria meningitidis infection. MolMicrobiol 60: 963-972.
7. Beernink P.T., Welsch JA, Harrison LH, Leipus A, Kaplan SL, Granoff DM. 2007. Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: Implications for the development of a multicomponent group B vaccine. J Infect Dis 195: 1472-1479.
8. Beernink P.T., Shaughnessy J, Braga EM, Liu Q, Rice PA, Ram S., Granoff DM. 2011. A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J Immunol 186: 3606-3614.
9. Berlanda Scorza F, Doro F, Rodriguez-Ortega MJ, Stella M, Liberatori S., Taddei AR, Serino L, Gomes Moriel D, Nesta B., Fontana MR, et al. 2008. Proteomics characterization of outer membrane vesicles from the extraintestinal pathogenic Escherichia coli DtolR IHE3034 mutant. Mol Cell Proteomics 7: 473-485.
10. Bernstein A., Pulendran B, Rappuoli R. 2011. Systems vaccinomics: The road ahead for vaccinology. OMICS 15: 529-531.
11. Borrow R., Carlone GM, Rosenstein N, Blake M, Feavers I, MartinD, ZollingerW, Robbins J, Aaberge I, GranoffDM, et al. 2006. Neisseria meningitidis group B correlates of protection and assay standardization-International meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine 24: 5093-5107.
12. Brehony C., Jolley KA, Maiden MC. 2007. Multilocus sequence typing for global surveillance of meningococcal disease. FEMS Microbiol Rev 31: 15-26.
13. Brehony C., Wilson DJ, Maiden MC. 2009. Variation of the factor H-binding protein of Neisseria meningitidis. Microbiology 155: 4155-4169.
14. Burton DR. 2010. Scaffolding to build a rational vaccine design strategy. Proc Natl Acad Sci 107: 17859-17860.
15. Buynak E.B., Roehm RR, Tytell AA, Bertland AU II, Lampson G.P., Hilleman MR. 1976. Vaccine against human hepatitis B. JAMA 235: 2832-2834.
16. Cantini F., Veggi D, Dragonetti S, Savino S, Scarselli M, Romagnoli G., Pizza M, Banci L, Rappuoli R. 2009. Solution structure of the factor H binding protein, a survival factor and protective antigen of Neisseria meningitidis. J Biol Chem 284: 9022-9026.
17. Capecchi B., Adu-Bobie J, Di Marcello F, Ciucchi L, Masignani V., Taddei A, Rappuoli R, Pizza M, Arico B. 2005. Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol 55: 687-698.
18. Comanducci M., Bambini S, Brunelli B, Adu-Bobie J, Arico B., Capecchi B, Giuliani MM, Masignani V, Santini L, Savino S, et al. 2002. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med 195: 1445-1454.
19. Davila S., Wright VJ, Khor CC, Sim KS, Binder A, Breunis W.B., Inwald D, Nadel S, Betts H, Carrol ED, et al. 2010. Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease. Nat Genet 42: 772-776.
20. de Bakker PI, Telenti A. 2010. Infectious diseases not immune to genome-wide association. Nat Genet 42: 731-732.
21. Dhiman N., Smith DI, Poland GA. 2009. Next-generation sequencing: Atransformative tool for vaccinology. Expert Rev Vaccines 8: 963-967.
22. Dhiman N., Haralambieva IH, Kennedy RB, Vierkant RA, O'Byrne MM, Ovsyannikova IG, Jacobson RM, Poland GA. 2010. SNP/haplotype associations in cytokine and cytokine receptor genes and immunity to rubella vaccine. Immunogenetics 62: 197-210.
23. Donati C., Hiller NL, Tettelin H, Muzzi A, Croucher NJ, Angiuoli S.V., Oggioni M, Dunning Hotopp JC, Hu FZ, Riley D.R., et al. 2010. Structure and dynamics of the pangenome of Streptococcus pneumoniae and closely related species. Genome Biol 11: R107.
24. Donnelly J., Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C., Moxon ER, Stella M, Comanducci M, Bambini S, et al. 2010. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci 107: 19490-19495.
25. Dormitzer P.R., Ulmer JB, Rappuoli R. 2008. Structure-based antigen design: A strategy for next generation vaccines. Trends Biotechnol 26: 659-667.
26. Dramsi S., Caliot E, Bonne I, Guadagnini S, Prevost MC, Kojadinovic M., Lalioui L, Poyart C, Trieu-Cuot P. 2006. Assembly and role of pili in group B streptococci. Mol Microbiol 60: 1401-1413.
27. Dunphy K.Y., Beernink PT, Brogioni B, Granoff DM. 2011. Effect of factor H-binding protein sequence variation on factor H binding and survival of Neisseria meningitidis in human blood. Infect Immun 79: 353-359.
28. Ellis RW. 1990. Newand improved vaccines against hepatitis B. In New generation vaccines (ed. Woodrow G, Levine M), pp. 439-447. Marcel Dekker, New York.
29. Findlow J., Borrow R, Snape MD, Dawson T, Holland A, John T.M., Evans A, Telford KL, Ypma E, Toneatto D, et al. 2010. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinantMeningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 51: 1127-1137.
30. Fletcher L.D., Bernfield L, Barniak V, Farley JE, Howell A, Knauf M., Ooi P, Smith RP, Weise P, Wetherell M, et al. 2004. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 72: 2088-2100.
31. Frasch C.E., Borrow R, Donnelly J. 2009. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 27 (Suppl 2): B112-B116.
32. Garcon N., Wettendorff M, Van Mechelen M. 2011. Role of AS04 in human papillomavirus vaccine: Mode of action and clinical profile. Expert Opin Biol Ther 11: 667-677.
33. Gaucher D., Therrien R, Kettaf N, Angermann BR, Boucher G, Filali-Mouhim A, Moser JM, Mehta RS, Drake DR III, Castro E, et al. 2008. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 205: 3119-3131.
34. Gill C.J., Baxter R, Anemona A, Ciavarro G, Dull P. 2010. Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo) or Menactra among healthy adolescents. Hum Vaccin 6: 881-887.
35. Giuliani M.M., Adu-Bobie J, Comanducci M, Arico B, Savino S., Santini L, Brunelli B, Bambini S, Biolchi A, Capecchi B., et al. 2006. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci 103: 10834-10839.
36. Giuliani M.M., Biolchi A, Serruto D, Ferlicca F, Vienken K, Oster P., Rappuoli R, Pizza M, Donnelly J. 2010. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine 28: 5023-5030.
37. Glenny A.T., Hopkins BE. 1923. Diphtheria toxoid as an immunizing agent. Br J Exp Pathol 4: 283-288.
38. Gotschlich E.C., Goldschneider I, Artenstein MS. 1969. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med 129: 1367-1384.
39. Granoff D.M., Welsch JA, Ram S. 2009. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect Immun 77: 764-769.
40. Halperin S.A., Diaz-Mitoma F, Dull P, Anemona A, Ceddia F. 2010. Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers. Eur J Clin Microbiol Infect Dis 29: 259-267.
41. Haralambieva I.H., Poland GA. 2010. Vaccinomics, predictive vaccinology and the future of vaccine development. Future Microbiol 5: 1757-1760.
42. Haralambous E., Dolly SO, Hibberd ML, Litt DJ, Udalova IA, O'Dwyer C, Langford PR, Simon Kroll J, Levin M. 2006. Factor H., a regulator of complement activity, is a major determinant of meningococcal disease susceptibility in UK Caucasian patients. Scand J Infect Dis 38: 764-771.
43. Hava D.L., Camilli A. 2002. Large-scale identification of serotype 4 Streptococcus pneumoniae virulence factors. Mol Microbiol 45: 1389-1406.
44. He M., Sebaihia M, Lawley TD, Stabler RA, Dawson LF, Martin M.J., Holt KE, Seth-Smith HM, Quail MA, Rance R., et al. 2010. Evolutionary dynamics of Clostridium difficile over short and long time scales. Proc Natl Acad Sci 107: 7527-7532.
45. Heinz E., Tischler P, Rattei T, Myers G, Wagner M, Horn M. 2009. Comprehensive in silico prediction and analysis of chlamydial outer membrane proteins reflects evolution and life style of the Chlamydiae. BMC Genomics 10: 634.
46. Hilleringmann M., Ringler P, Muller SA, De Angelis G, Rappuoli R., Ferlenghi I, Engel A. 2009. Molecular architecture of Streptococcus pneumoniae TIGR4 pili. EMBO J 28: 3921-3930.
47. Jacobsson S., Molling P, Olcen P. 2009. Seroprevalence of antibodies against fHbp andNadA, two potential vaccine antigens for Neisseria meningitidis. Vaccine 27: 5755-5759.
48. Jefferies J.M., Macdonald E, Faust SN, Clarke SC. 2011. 13-valent pneumococcal conjugate vaccine (PCV13). Hum Vaccin 7: 1012-1018.
49. Jiang H.Q., Hoiseth SK, Harris SL, McNeil LK, ZhuD, Tan C, Scott A.A., Alexander K, Mason K, Miller L, et al. 2010. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 28: 6086-6093.
50. Keiser P.B., Biggs-Cicatelli S, Moran EE, Schmiel DH, Pinto V.B., Burden RE, Miller LB, Moon JE, Bowden RA, Cummings J.F., et al. 2011. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine 29: 1413-1420.
51. Kelly D.F., Moxon ER, Pollard AJ. 2004. Haemophilus influenzae type b conjugate vaccines. Immunology 113: 163-174.
52. Kitano H. 2002. Systems biology: A brief overview. Science 295: 1662-1664.
53. Kitchin NR. 2011. Review of diphtheria, tetanus and pertussis vaccines in clinical development. Expert Rev Vaccines 10: 605-615.
54. Koeberling O., Delany I, Granoff DM. 2011a. A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines. Clin Vaccine Immunol 18: 736-742.
55. Koeberling O., Seubert A, Santos G, Colaprico A, Ugozzoli M., Donnelly J, Granoff DM. 2011b. Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys. Vaccine 29: 4728-4734.
56. Kruskall M.S., Alper CA, Awdeh Z, Yunis EJ, Marcus-Bagley D. 1992. The immune response to hepatitis B vaccine in humans: Inheritance patterns in families. J Exp Med 175: 495-502.
57. Lauer P., Rinaudo CD, Soriani M, Margarit I, Maione D, Rosini R., Taddei AR, Mora M, Rappuoli R, Grandi G, et al. 2005. Genome analysis reveals pili in Group B Streptococcus. Science 309: 105.
58. Lawley T.D., Croucher NJ, Yu L, Clare S, Sebaihia M, Goulding D, Pickard DJ, Parkhill J, Choudhary J, Dougan G. 2009. Proteomic and genomic characterization of highly infectious Clostridium difficile 630 spores. J Bacteriol 191: 5377-5386.
59. LeMieux J, Hava DL, Basset A, Camilli A. 2006. RrgA and RrgB are components of a multisubunit pilus encoded by the Streptococcus pneumoniae rlrA pathogenicity islet. Infect Immun 74: 2453-2456.
60. Levine M.M., Lagos R. 2004. Vaccines and vaccination in historical perspective. In New generation vaccines (ed. Levine M.M., Kaper JB, Rappouli R, et al.), pp. 1-10. Marcel Dekker, New York.
61. Liu X., Afrane M, Clemmer DE, Zhong G, Nelson DE. 2010. Identification of Chlamydia trachomatis outer membrane complex proteins by differential proteomics. J Bacteriol 192: 2852-2860.
62. MacLeod CM, Hodges GR, Heidelberger M, BernhardWG. 1945. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J Exp Med 82: 445-465.
63. Madico G., Welsch JA, Lewis LA, McNaughton A, Perlman DH, Costello CE, Ngampasutadol J, Vogel U, Granoff D.M., Ram S. 2006. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 177: 501-510.
64. Maione D., Margarit I, Rinaudo CD, Masignani V, Mora M, Scarselli M., Tettelin H, Brettoni C, Iacobini ET, Rosini R, et al. 2005. Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science 309: 148-150.
65. Manetti A.G., Zingaretti C, Falugi F, Capo S, Bombaci M, Bagnoli F., Gambellini G, Bensi G, Mora M, Edwards AM, et al. 2007. Streptococcus pyogenes pili promote pharyngeal cell adhesion and biofilm formation. Mol Microbiol 64: 968-983.
66. Margarit I., Rinaudo CD, Galeotti CL, Maione D, Ghezzo C, Buttazzoni E., Rosini R, Runci Y, Mora M, Buccato S, et al. 2009. Preventing bacterial infections with pilus-based vaccines: The group B streptococcus paradigm. J Infect Dis 199: 108-115.
67. Masignani V., Comanducci M, Giuliani MM, Bambini S, Adu-Bobie J, Arico B, Brunelli B, Pieri A, Santini L, Savino S., et al. 2003. Vaccination against Neisseria meningitidis using three variants of the lipoproteinGNA1870. J Exp Med 197: 789-799.
68. Mazmanian S.K., Liu G, Jensen ER, Lenoy E, Schneewind O. 2000. Staphylococcus aureus sortase mutants defective in the display of surface proteins and in the pathogenesis of animal infections. Proc Natl Acad Sci 97: 5510-5515.
69. Mbow M.L., De Gregorio E, Valiante NM, Rappuoli R. 2010. New adjuvants for human vaccines. Curr Opin Immunol 22: 411-416.
70. McCarthy AJ, Lindsay JA. 2010. Genetic variation in Staphylococcus aureus surface and immune evasion genes is lineage associated: Implications for vaccine design and host-pathogen interactions. BMC Microbiol 10: 173.
71. McNeil LK, Murphy E, Zhao XJ, Guttmann S, Harris SL, Scott A.A., Tan C, Mack M, DaSilva I, Alexander K, et al. 2009. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine 27: 3417-3421.
72. Meri S., Jordens M, Jarva H. 2008. Microbial complement inhibitors as vaccines. Vaccine 26: I113-I117.
73. Montigiani S., Falugi F, Scarselli M, Finco O, Petracca R, Galli G., Mariani M, Manetti R, Agnusdei M, Cevenini R, et al. 2002. Genomic approach for analysis of surface proteins in Chlamydia pneumoniae. Infect Immun 70: 368-379.
74. Mora M., Bensi G, Capo S, Falugi F, Zingaretti C, ManettiAG, Maggi T., Taddei AR, Grandi G, Telford JL. 2005. Group A streptococcus produce pilus-like structures containing protective antigens and Lancefield T antigens. Proc Natl Acad Sci 102: 15641-15646.
75. Morens D.M., Folkers GK, Fauci AS. 2008. Emerging infections: A perpetual challenge. Lancet Infect Dis 8: 710-719.
76. Moriel D.G., Bertoldi I, Spagnuolo A, Marchi S, Rosini R, Nesta B., Pastorello I, Corea VA, Torricelli G, Cartocci E, et al. 2010. Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli. Proc Natl Acad Sci 107: 9072-9077.
77. Murphy E., Andrew L, Lee KL, Dilts DA, Nunez L, Fink PS, Ambrose K., Borrow R, Findlow J, Taha MK, et al. 2009. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 200: 379-389.
78. Nakaya H.I., Li S, Pulendran B. 2011. Systems vaccinology: Learning to compute the behavior of vaccine induced immunity. Wiley Interdiscip Rev Syst Biol Med 4: 193-205.
79. Nesta B., Spraggon G, Alteri C, Moriel DG, Rosini R, VeggiD, Smith S., Bertoldi I, Pastorello I, Ferlenghi I, et al. 2012. FdeC, a novel broadly conserved Escherichia coli adhesin eliciting protection against urinary tract infections. MBio 3: e00010-12.
80. Nielsen H.E., Christensen KC, Koch C, Thomsen BS, Heegaard NH, Tranum-Jensen J. 1989. Hereditary, complete deficiency of complement factorHassociated with recurrent meningococcal disease. Scand J Immunol 30: 711-718.
81. Nuccitelli A., Cozzi R, Gourlay LJ, Donnarumma D, Necchi F., Norais N, Telford JL, Rappuoli R, Bolognesi M, Maione D., et al. 2011. Structure-based approach to rationally design a chimeric protein for an effective vaccine against Group B Streptococcus infections. Proc Natl Acad Sci 108: 10278-10283.
82. O'Hagan DT, Rappuoli R, De Gregorio E, Tsai T, Del Giudice G. 2011. MF59 adjuvant: The best insurance against influenza strain diversity. Expert Rev Vaccines 10: 447-462.
83. Oriente F., Scarlato V, Delany I. 2010. Expression of factor H binding protein of meningococcus responds to oxygen limitation through a dedicated FNR-regulated promoter. J Bacteriol 192: 691-701.
84. Ovsyannikova I.G., Jacobson RM, Vierkant RA, Pankratz VS, Poland GA. 2007. HLA supertypes and immune responses to measles-mumps-rubella viral vaccine: Findings and implications for vaccine design. Vaccine 25: 3090-3100.
85. Parida S.K., Kaufmann SH. 2010. Novel tuberculosis vaccines on the horizon. Curr Opin Immunol 22: 374-384.
86. Peltola H., Kayhty H, Sivonen A, Makela H. 1977. Haemophilus influenzae type b capsular polysaccharide vaccine in children: A double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland. Pediatrics 60: 730-737.
87. Pezzicoli A., Santi I, Lauer P, Rosini R, Rinaudo D, Grandi G, Telford J.L., Soriani M. 2008. Pilus backbone contributes to group B Streptococcus paracellular translocation through epithelial cells. J Infect Dis 198: 890-898.
88. Pizza M., Covacci A, Bartoloni A, Perugini M, Nencioni L, DeMagistrisMT, Villa L, NucciD, Manetti R, Bugnoli M, et al. 1989. Mutants of pertussis toxin suitable for vaccine development. Science 246: 497-500.
89. Pizza M., Scarlato V, Masignani V, Giuliani MM, Arico B, Comanducci M., Jennings GT, Baldi L, Bartolini E, Capecchi B., et al. 2000. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287: 1816-1820.
90. Pizza M., Donnelly J, Rappuoli R. 2008. Factor H-binding protein, a unique meningococcal vaccine antigen. Vaccine 26 (Suppl 8): 146-148.
91. Plested J.S., Welsch JA, Granoff DM. 2009. Ex vivo model of meningococcal bacteremia using human blood for measuring vaccine-induced serum passive protective activity. Clin Vaccine Immunol 16: 785-791.
92. Plotkin SA. 2009. Vaccines: The fourth century. Clin Vaccine Immunol 16: 1709-1719.
93. Poland G.A., Ovsyannikova IG, Jacobson RM, Smith DI. 2007. Heterogeneity in vaccine immune response: The role of immunogenetics and the emerging field of vaccinomics. Clin Pharmacol Ther 82: 653-664.
94. Poland G.A., Ovsyannikova IG, Jacobson RM. 2008. Personalized vaccines: The emerging field of vaccinomics. Expert Opin Biol Ther 8: 1659-1667.
95. Poland G.A., Ovsyannikova IG, Jacobson RM. 2009. Application of pharmacogenomics to vaccines. Pharmacogenomics 10: 837-852.
96. Pulendran B., Li S, Nakaya HI. 2010. Systems vaccinology. Immunity 33: 516-529.
97. Querec T.D., Akondy RS, Lee EK, Cao W, Nakaya HI, Teuwen D., Pirani A, Gernert K, Deng J, Marzolf B, et al. 2009. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 10: 116-125.
98. Ramon G. 1924. Sur la toxine et sur l'anatoxine diphtériques. Pouvoir floculant et propriétés immunisantes. Ann Inst Pasteur 38: 1-106.
99. Rappuoli R. 2007. Bridging the knowledge gaps in vaccine design. Nat Biotechnol 25: 1361-1366.
100. Rappuoli R., Black S, Lambert PH. 2011. Vaccine discovery and translation of new vaccine technology. Lancet 378: 360-368.
101. RaskoDA, Rosovitz MJ, Myers GS, Mongodin EF, FrickeWF, Gajer P., Crabtree J, Sebaihia M, Thomson NR, Chaudhuri R, et al. 2008. The pangenome structure of Escherichia coli: Comparative genomic analysis of E. coli commensal and pathogenic isolates. J Bacteriol 190: 6881-6893.
102. Rinaudo C.D., Telford JL, Rappuoli R, Seib KL. 2009. Vaccinology in the genome era. J Clin Invest 119: 2515-2525.
103. Rinaudo C.D., Rosini R, Galeotti CL, Berti F, Necchi F, Reguzzi V., Ghezzo C, Telford JL, Grandi G, Maione D. 2010. Specific involvement of pilus type 2a in biofilm formation in group B Streptococcus. PLoS ONE 5: e9216.
104. Rosini R., Rinaudo CD, Soriani M, Lauer P, Mora M, Maione D., Taddei A, Santi I, Ghezzo C, Brettoni C, et al. 2006. Identification of novel genomic islands coding for antigenic pilus-like structures in Streptococcus agalactiae. Mol Microbiol 61: 126-141.
105. Scarselli M., Arico B, Brunelli B, Savino S, Di Marcello F, Palumbo E., VeggiD, Ciucchi L, Cartocci E, BottomleyMJ, et al. 2011. Rational design of a meningococcal antigen inducing broad protective immunity. Sci Transl Med 3: 91ra62.
106. Schneider M.C., Exley RM, Chan H, Feavers I, Kang YH, Sim R.B., Tang CM. 2006. Functional significance of factor H binding to Neisseria meningitidis. J Immunol 176: 7566-7575.
107. Schneider M.C., Prosser BE, Caesar JJ, Kugelberg E, Li S, Zhang Q., Quoraishi S, Lovett JE, Deane JE, Sim RB, et al. 2009. Neisseria meningitidis recruits factor H using protein mimicryof host carbohydrates. Nature 458: 890-893.
108. Seib K.L., Serruto D, Oriente F, Delany I, Adu-Bobie J, Veggi D., Arico B, Rappuoli R, Pizza M. 2009. Factor Hbinding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. Infect Immun 77: 292-299.
109. Seib K.L., Brunelli B, Brogioni B, Palumbo E, Bambini S, Muzzi A., Dimarcello F, Marchi S, van der Ende A, Arico B., et al. 2011. Characterisation of diverse sub-variants of the meningococcal factor H binding protein (fHbp) for their ability to bind fH, mediate serum resistance and induce bactericidal antibodies. Infect Immun 79: 970-981.
110. Serruto D., Spadafina T, Ciucchi L, Lewis LA, Ram S, Tontini M., Santini L, Biolchi A, Seib KL, Giuliani MM, et al. 2010. Neisseria meningitidis GNA2132, a heparinbinding protein that induces protective immunity in humans. Proc Natl Acad Sci 107: 3770-3775.
111. Stabler R.A., Gerding DN, Songer JG, Drudy D, Brazier JS, Trinh H.T., Witney AA, Hinds J, Wren BW. 2006. Comparative phylogenomics of Clostridium difficile reveals clade specificity and microevolution of hypervirulent strains. J Bacteriol 188: 7297-7305.
112. Stabler R.A., He M, Dawson L, Martin M, Valiente E, Corton C., Lawley TD, Sebaihia M, Quail MA, Rose G, et al. 2009. Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome Biol 10: R102.
113. Stranger-Jones YK, Bae T, Schneewind O. 2006. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc Natl Acad Sci 103: 16942-16947.
114. Telford J.L., Barocchi MA, Margarit I, Rappuoli R, Grandi G. 2006. Pili in gram-positive pathogens. Nat Rev Microbiol 4: 509-519.
115. Tettelin H., Masignani V, Cieslewicz MJ, Donati C, Medini D, Ward N.L., Angiuoli SV, Crabtree J, Jones AL, Durkin AS, et al. 2005. Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: Implications for the microbial "pan-genome. " Proc Natl Acad Sci 102: 13950-13955.
116. Thorpe C., Edwards L, Snelgrove R, Finco O, Rae A, Grandi G., Guilio R, Hussell T. 2007. Discovery of a vaccine antigen that protects mice from Chlamydia pneumoniae infection. Vaccine 25: 2252-2260.
117. Tobin G.J., Trujillo JD, Bushnell RV, Lin G, Chaudhuri AR, Long J., Barrera J, Pena L, Grubman MJ, Nara PL. 2008. Deceptive imprinting and immune refocusing in vaccine design. Vaccine 26: 6189-6199.
118. Toneatto D., Ismaili S, Ypma E, Vienken K, Oster P, Dull P. 2011a. The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans. Hum Vaccin 7: 646-653.
119. Toneatto D., Oster P, Deboer AC, Emerson A, Santos GF, Ypma E., Detora L, Pizza M, Kimura A, Dull P. 2011b. Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults. Hum Vaccin 7: 781-791.
120. Veggi D., Gentile MA, Cantini F, Lo Surdo P, Nardi-Dei V, Seib K.L., Pizza M, Rappuoli R, Banci L, Savino S, et al. 2012. The factor H binding protein of Neisseria meningitidis interacts with xenosiderophores in vitro. Biochemistry 51: 9384-9393.
121. Welsch J.A., Ram S, Koeberling O, Granoff DM. 2008. Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J Infect Dis 197: 1053-1061.